A randomized blind trial of Iopamidol and meglumine calcium metrizoate (Triosil 280, Isopaque Cerebral) in cerebral angiography.
A randomized blind trial of iopamidol and meglumine calcium metrizoate (Triosil 280, Isopaque Cerebral) for cerebral angiography was performed in 20 patients. The Iopamidol was better tolerated and caused significantly less discomfort in patients than metrizoate. There was no difference in the quality of the radiographs. A further 13 patients also received Iopamidol for cerebral angiography with similar results. No adverse effects were observed in any of the patients. Our evidence suggests that Iopamidol has significant advantages over currently available contrast media for cerebral angiography.
D002533:Cerebral Angiography; D002986:Clinical Trials as Topic; D003287:Contrast Media; D006801:Humans; D007463:Iodobenzoates; D007479:Iopamidol; D007483:Iothalamic Acid / Q000031:analogs & derivatives*; D008794:Metrizoic Acid / Q000031:analogs & derivatives; D011897:Random Allocation
D003287:Contrast Media; D007463:Iodobenzoates; D007483:Iothalamic Acid; D008794:Metrizoic Acid; D007479:Iopamidol; C021342:methylglucamine metrizoate